Overview: OncoPro HRR Germline NGS TestIntroduction: The OncoPro HRR Germline NGS Test screens homologous recombination repair (HRR) genes to assess cancer risk, aiding treatment planning. Following 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding risk assessment, treatment planning, and improving outcomes in molecular pathology for patients with suspected hereditary cancers, particularly those responsive to PARP inhibitors.
Other Names: HRR Germline Assay, HRR Cancer Risk Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HRR gene testing began in the 2010s with PARP inhibitor research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Screens HRR genes to assess hereditary cancer risk, guides treatment, and evaluates patients with a family history of cancer.
Test Parameters: 1. HRR Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report family history of cancer or HRR-related symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document family history of breast, ovarian, or prostate cancer, or personal cancer history. Include current medications, especially PARP inhibitors.
Consent: Written consent required, detailing the tests purpose, HRR cancer risk implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to screen HRR genes (e.g., BRCA1, BRCA2, ATM). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for HRR-related cancer risk assessment.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations indicate increased cancer risk, guiding PARP inhibitor therapy or preventive measures. Negative results may require clinical follow-up.
Specialist Consultation: Consult a geneticist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Tumor profiling, imaging (CT/MRI), or tumor markers to confirm HRR-related cancer diagnosis.
Test Limitations: Not all HRR-related cancers are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO HRR Guidelines, 2023; Journal of Clinical Oncology, Tutt A, 2022.
